報價延遲最少15分鐘:2025/06/04 03:41 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
18.44 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-3.23/-3.79
|
|
企業價值
439.55M
|
| 資產負債 |
|
每股賬面淨值
10.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/04 03:41 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases. |